ライフサイエンスコーパス: pseudosubstrate

1 Ch and PMA was blocked by Ro-31-8425 or beta-pseudosubstrate.

2 on and dephosphorylation requires an exposed pseudosubstrate.

3 n cAMP-dependent protein kinase upon binding pseudosubstrate.

4 not by the alpha, delta, or alpha beta gamma pseudosubstrate.

5 d-type aPKC, but not a construct lacking the pseudosubstrate.

6 ylation, as it was inhibited by the PKC-zeta pseudosubstrate.

7 rate but not by the alpha, delta, or epsilon pseudosubstrate.

8 plex bound to a peptide sequence acting as a pseudosubstrate.

9 dies suggest that PIP3 binds directly to the pseudosubstrate.

10 tophosphorylated C-termini act as inhibitory pseudosubstrates.

11 hows desulfation activity toward arylsulfate pseudosubstrates.

12 Fs) by treating C2C12 myotubes with PKCtheta pseudosubstrates.

13 A PKCzeta pseudosubstrate, a specific blocker of aPKC activity, an

14 activity by myristoylated PKC (zeta/lambda) pseudosubstrate, a specific inhibitor of PKCzeta, and Go

15 This pseudosubstrate affinity assay can detect variations in

16 peptide, myristoylated protein kinase C-zeta pseudosubstrate, also significantly decreased the entero

17 interaction activates aPKC by displacing the pseudosubstrate, although full activity requires the Par

18 atory module of aPKCiota, comprising the PB1 pseudosubstrate and C1 domains, forms a cooperative and

19 The pseudosubstrate and C1a domains, however, are minimally

20 Myristoylated PKC (zeta/lambda) pseudosubstrate and DN PKCzeta also inhibited cAMP-induc

21 atalysis; and exposure of the amino-terminal pseudosubstrate and masking of the carboxyl terminus acc

22 We find that Acm1 uses pseudosubstrate and other sequence motifs to bind and in

23 Moreover, although substrates/pseudosubstrate and products independently close the act

24 nzyme activity in vitro by both the PKC-zeta pseudosubstrate and RO 31-8220 correlated well with inhi

25 gulatory region of PKCepsilon containing the pseudosubstrate and zinc finger-like sequences was found

26 ptical methods that often require the use of pseudosubstrates and associated dyes.

27 tanol, cell-permeable myristoylated PKC-zeta pseudosubstrate, and expression of kinase-inactive RAF,

28 y many viral antagonists, including poxvirus pseudosubstrate antagonists that mimic the natural subst

29 This differs from the more usual pseudosubstrate approach to enzyme inhibition.

30 dicating that AutoN does not act as a simple pseudosubstrate as suggested previously.

31 In living cells, zVAD-FMK, a pseudosubstrate aspartase inhibitor, blocked the activit

32 The effects of substrate/pseudosubstrate (ATP and PKI(5-24)), a fragment of prote

33 dependent/conformational-dependent relief of pseudosubstrate autoinhibition.

34 y a short junction sequence which contains a pseudosubstrate autoinhibitor.

35 th kinase was mapped to what appears to be a pseudosubstrate autoinhibitory domain at the extreme car

36 lly falls into two categories: regulation by pseudosubstrate autoinhibitory domains, and remodeling o

37 Some compounds such as pseudosubstrate-based peptide inhibitor binds to the pep

38 GIYWHHY, we designed and synthesized several pseudosubstrate-based peptide inhibitors.

39 in, that demonstrate the molecular basis for pseudosubstrate binding to the active state with phospho

40 impairs eIF2alpha phosphorylation and viral pseudosubstrate binding.

41 Kinetic analyses demonstrated this pseudosubstrate binds the active site and strongly stimu

42 Both RO 31-8220 and myristoylated PKC-zeta pseudosubstrate blocked insulin-induced activation and a

43 mtide-2-related inhibitory peptide (AIPm), a pseudosubstrate blocker of CaMKII, whereas axotomized ne

44 tion of ESO cells was reduced by the epsilon pseudosubstrate but not by the alpha, delta, or alpha be

45 ES cells was reduced by the alpha beta gamma pseudosubstrate but not by the alpha, delta, or epsilon

46 gene, drumstick (drm), which functions as a pseudosubstrate by displacing Bowl from the Hyd-Lin comp

47 /methionine is cleaved at the amino-terminal pseudosubstrate by the endoproteinase Arg-C.

48 he complex formation of C1s with its natural pseudosubstrate, C1 inhibitor (C1 inh), and promotion of

49 (C1a, C1b, and C2) appears to strengthen the pseudosubstrate-catalytic domain interaction in a nucleo

50 ing to PKCgamma was initially prevented by a pseudosubstrate clamp, which kept the diacylglycerol-bin

51 ion or exposure for 1 hour to myristoylated, pseudosubstrate-derived peptide inhibitors against PKCal

52 Pseudosubstrate-derived peptides, like ZIP, are thought

53 ticity and memory have relied on the PKCzeta pseudosubstrate-derived zeta-inhibitory peptide (ZIP).

54 h RVPO (>12 fold), and phosphorylated in the pseudosubstrate domain at the Ser-411, Thr-421, and Ser-

55 g of the active PKA catalytic subunit to its pseudosubstrate domain inhibitor (PKI) fused with glutat

56 We find that whereas the pseudosubstrate domain is necessary for autoinhibition i

57 hobic residue (Val(125)) within the putative pseudosubstrate domain of cGKII.

58 ated a knock-in mouse with a mutation in the pseudosubstrate domain of PKCy, which keeps PKCy in the

59 e corresponding to the unique PKCiota/lambda pseudosubstrate domain was introduced into an in vitro a

60 cted residues in the putative autoinhibitory pseudosubstrate domain, as well as threonine 389.

61 egulatory elements, including the inhibitory pseudosubstrate domain, consequently rendering the kinas

62 elated to SCA14 with a point mutation in the pseudosubstrate domain, PKCy-A24E, known to induce a con

63 horylation sites at Thr(141) adjacent to the pseudosubstrate domain, Thr(218) in the C1A-C1B interdom

64 ain bears a striking resemblance to the SOCS pseudosubstrate domain, we examined whether Jak-2 associ

65 58 was examined due to its proximity to the pseudosubstrate domain.

66 While the action of pseudosubstrate domains can be explained by simple compe

67 alytic, kinase extension, and autoinhibitory pseudosubstrate domains, was identified.

68 Ca2+-binding, diacylglycerol-activation and pseudosubstrate domains.

69 (EPSP) synthase has been examined using the pseudosubstrates, (E)- and (Z)-3-fluorophosphoenolpyruva

70 Based on our proposed "pseudosubstrate envelope" concept, 25 benzothiazole-bear

71 d HIV-1 CA within the chemical space of the "pseudosubstrate envelope".

72 itory associations between caspase-1 and its pseudosubstrate, Flightless I (FliI), while RNF34 ubiqui

73 HF), the product tetrahydrofolate (THF), the pseudosubstrate folate, reduced and oxidized NADPH cofac

74 toylated peptide based on the autoinhibitory pseudosubstrate fragment of the atypical PKCzeta, zeta i

75 KI), an inhibitor of a novel PKC (an nPKCeta pseudosubstrate fragment), and an antioxidant (melatonin

76 ides the energy to release an autoinhibitory pseudosubstrate from the active site.

77 may reflect the energy required to expel the pseudosubstrate from the substrate binding cavity.

78 phosphorylation site, a presumptive PKC-beta pseudosubstrate, gave similar results.

79 or substrates of AMPK, inhibit the kinase as pseudosubstrates in a Rapamycin-regulated fashion in vit

80 S-Adenosylhomocysteine acted as a pseudosubstrate, in that it did not undergo either acyla

81 Inhibition of PKC-zeta using PKC-zeta pseudosubstrate inhibited IL-1beta-stimulated increases

82 Inhibition of PKC-theta and PKC-zeta using pseudosubstrates inhibited IL-1beta-stimulated activatio

83 PC/C inhibitors have been reported to act as pseudosubstrates, inhibiting the APC/C by preventing sub

84 This pseudosubstrate inhibition of AMPK by LiRP proteins redu

85 ty of ubiquitinatable lysines contributes to pseudosubstrate inhibition of APC(Cdh1).

86 Our results reveal a simple, elegant mode of pseudosubstrate inhibition that combines high-affinity a

87 the PKR kinase domain can drastically impact pseudosubstrate inhibition while leaving substrate phosp

88 Pseudosubstrate inhibition, a commonly observed mechanis

89 p78 inhibits PKA and PRKX kinase activity by pseudosubstrate inhibition.

90 ow APC/C activity is suppressed by the small pseudosubstrate inhibitor Acm1 from budding yeast (Sacch

91 Using a selective, cell-permeable zeta-pseudosubstrate inhibitor at concentrations that block p

92 P specifically associated with the caspase-1 pseudosubstrate inhibitor Flightless-1 and its binding p

93 erminal portion of the BPS region binds as a pseudosubstrate inhibitor in the substrate peptide bindi

94 ir ability to escape inhibition by the model pseudosubstrate inhibitor K3, encoded by the vaccinia vi

95 ential and that soluble BubR1 functions as a pseudosubstrate inhibitor of APC/C(Cdc20) during interph

96 These findings implicate Mad3p as a pseudosubstrate inhibitor of APCCdc20, competing with AP

97 We detected homology between a cellular pseudosubstrate inhibitor of PKA, the protein kinase inh

98 because it was not inhibited by the specific pseudosubstrate inhibitor of PKC, PKC(19-31), and it was

99 ing NMDA receptors using an isoform-specific pseudosubstrate inhibitor of PKCzeta.

100 nalysis on the vaccinia virus K3L protein, a pseudosubstrate inhibitor of PKR.

101 Addition of a pseudosubstrate inhibitor of the Ca2+-calmodulin-depende

102 r, in the presence of an N-myristoylated PKC pseudosubstrate inhibitor peptide (MyrPsiPKC-I(19-27)),

103 vation of Kv3.3 currents, and a specific PKC pseudosubstrate inhibitor peptide prevented the effects

104 phosphatidylserine and blocked by excess PKC pseudosubstrate inhibitor peptide.

105 In permeabilized 3T3-L1 cells, addition of pseudosubstrate inhibitor peptides of casein kinase II (

106 he atypical PKCzeta by myristoylated PKCzeta pseudosubstrate inhibitor significantly decreased the A(

107 PhK13 has been proposed to function as a pseudosubstrate inhibitor with Cys-308 occupying the sit

108 ither bisindolylmaleimide-I or a peptide PKC pseudosubstrate inhibitor, and COX-2 mRNA and protein we

109 y been shown to inhibit Cdc20 by acting as a pseudosubstrate inhibitor, but in this paper, we show th

110 Inhibition of PKCzeta by its pseudosubstrate inhibitor, or its siRNA, or dominant neg

111 p-regulation, an effect inhibited by the PKC pseudosubstrate inhibitor, PKC19-36.

112 Furthermore, excess amounts of the pseudosubstrate inhibitor, PKI(5-24), had no effect on t

113 effects were abolished by a PKCzeta-specific pseudosubstrate inhibitor.

114 -alkylating agents (e.g., temozolomide) with pseudosubstrate inhibitors (such as O(6)-benzylguanine)

115 FNIP1 ubiquitylation is gated by pseudosubstrate inhibitors of the BEX family, which prev

116 h untreated and ionophore-treated cells, but pseudosubstrate inhibitors only bound to TF-factor VIIa

117 Pharmacological tools and pseudosubstrate inhibitors suggested that these kinases

118 tantial differences in the concentrations of pseudosubstrate inhibitors which rescued cells from SOD1

119 model for how E3 substrates evolve to become pseudosubstrate inhibitors.

120 activity, as intrathecal delivery of a zeta-pseudosubstrate inhibitory peptide (PKCzeta-PS) 35 min f

121 and PIP3 current activation is blocked by a pseudosubstrate inhibitory peptide of atypical PKC but n

122 Intrahemocoel injections of the pseudosubstrate inhibitory peptide ZIP (zeta inhibitory

123 vation by PMA and inhibition of PKC with the pseudosubstrate inhibitory peptide.

124 f the PKA catalytic subunit (PKA-C) from the pseudosubstrate inhibitory sequence, drive RIalpha conde

125 and for residues 102-115, which include the pseudosubstrate inhibitory site, support the prediction

126 the idea that residues conserved between the pseudosubstrate K3L protein and the authentic substrate

127 nsulin, but not PIP(3), activated truncated, pseudosubstrate-lacking forms of PKC-zeta and PKC-lambda

128 This site, which we have termed the pseudosubstrate latch (PSL), resembles the consensus COP

129 Moreover, treatment with PKClambda/zeta pseudosubstrate lead to significant reduction of FGF2-me

130 However, truncation of a pseudosubstrate-like sequence in the C-terminus of DCK1

131 tate) and the inhibitors (high magnesium and pseudosubstrate) locking it into discrete minima (dynami

132 1+ by ran1+ and suggest that mei3+ employs a pseudosubstrate mechanism for its inhibitory function.

133 ructure of the Grp1 Sec7-PH tandem reveals a pseudosubstrate mechanism of autoinhibition in which the

134 E2, and these results are consistent with a pseudosubstrate mechanism of inhibition of eIF2alpha kin

135 emonstrate that instead of acting through a "pseudosubstrate" mechanism as previously hypothesized, E

136 e (-59AQKQAS-) that is amino-terminal to the pseudosubstrate motif (-74KRQAI-).

137 re regulated by an N-terminal autoinhibitory pseudosubstrate motif centered on a critical proline res

138 ncovered evolution of an unusual stimulatory pseudosubstrate motif in Cdc14 phosphatases.

139 a peptide (uPEP2) containing the typical PKC pseudosubstrate motif present in all PKCs that autoinhib

140 htly bound securin protein, which contains a pseudosubstrate motif that blocks the separase active si

141 within its NH(2)-terminal regulatory half, a pseudosubstrate motif that occupies the kinase active si

142 First, it blocks PKAC activity via a pseudosubstrate motif, akin to the mechanism employed by

143 Degrons are also employed as pseudosubstrate motifs by APC/C inhibitors, and pseudosu

144 DK1-cyclin B1 inhibits separase by deploying pseudosubstrate motifs from intrinsically disordered loo

145 In both complexes, separase is inhibited by pseudosubstrate motifs that block substrate binding at t

146 bitor Acm1, which incorporates D and KEN box pseudosubstrate motifs, we describe the molecular basis

147 and yeast(8), human securin contains its own pseudosubstrate motifs.

148 ave previously shown that the autoinhibitory pseudosubstrate must be removed from the active site in

149 udosubstrate motifs by APC/C inhibitors, and pseudosubstrates must bind their cognate activators tigh

150 and (d) react with the low molecular weight pseudosubstrate, O6-benzylguanine.

151 ic surface, resulting in displacement of the pseudosubstrate of aPKC and re-engagement in the substra

152 These data support a model in which the pseudosubstrate of aPKCs is tethered to the acidic surfa

153 Cancer-associated hotspot mutations in the pseudosubstrate of PKCbeta that impair autoinhibition re

154 TR internalization by more than 50%, whereas pseudosubstrates of cyclic AMP-dependent kinase A, prote

155 emplate that acts as a reversible inhibitor (pseudosubstrate) of redox proteins.

156 rotein kinase C-zeta (PKC-zeta) inhibitor (a pseudosubstrate oligopeptide), but not a PKC-alphabeta i

157 protein kinase C zeta (PKC zeta) inhibitors (pseudosubstrate or small interfering RNA silencing).

158 hat purified recombinant PelA hydrolyzed the pseudosubstrate p-nitrophenyl acetate in vitro, and site

159 We first used the pseudosubstrate peptide (0.1 micromol/L in the pipette),

160 Strikingly, the enzyme is inhibited by the pseudosubstrate peptide Ala-Cys(-S-GlcNAc)-Ala, and has

161 Both the pseudosubstrate peptide and kinase-dead PKCiota/lambda i

162 Use of PKC agonists and isozyme-specific pseudosubstrate peptide antagonists suggested a role for

163 nanopore sensor for Pim kinases that bears a pseudosubstrate peptide attached by an enhanced engineer

164 rat kidney cells incubated with Rab2 and the pseudosubstrate peptide displayed abundant swollen or di

165 Addition of PKC-zeta pseudosubstrate peptide in vitro or myristoylated peptid

166 as prevented by intracellular perfusion of a pseudosubstrate peptide inhibitor for aPKCs.

167 This depression was partially blocked by a pseudosubstrate peptide inhibitor of cGMP-dependent prot

168 ation by DAG was specifically inhibited by a pseudosubstrate peptide inhibitor of cPKCs (PKC alpha(22

169 inase activates the subunit for binding to a pseudosubstrate peptide inhibitor of protein kinase A.

170 A pseudosubstrate peptide inhibitor of the atypical PKCs (

171 However, a pseudosubstrate peptide inhibitor specific for PKC-zeta

172 A cell-permeable PKCzeta pseudosubstrate peptide inhibitor was capable of blockin

173 substrate phosphorylation, with and without pseudosubstrate peptide inhibitor.

174 cells treated with a cell-permeable PKCzeta pseudosubstrate peptide inhibitor.

175 ion of protein kinase C activity utilizing a pseudosubstrate peptide sequence blocked IRES activity d

176 CTD can be inhibited specifically by a CDK7 pseudosubstrate peptide that also inhibits transcription

177 ihydroouabain to inhibit alpha2/3 and a zeta-pseudosubstrate peptide to inhibit PKMzeta.

178 When PKC zeta-specific inhibitory pseudosubstrate peptide was introduced into LLC-MK2 cell

179 Marinobufagenin, dihydroouabain, and zeta-pseudosubstrate peptide were used to determine if PKMzet

180 n 4% of the phosphorylation of the PKC-alpha pseudosubstrate peptide).

181 specific inhibitor (a myristoylated PKCzeta pseudosubstrate peptide).

182 inase, Rp-8Br-PET-cGMPS, KT5823, and a novel pseudosubstrate peptide, all block LTD.

183 orylation, or by intracellular delivery of a pseudosubstrate peptide, also disrupts sarcomeric organi

184 d 8, stimulated phosphorylation of the alpha-pseudosubstrate peptide, and in primary mouse keratinocy

185 cells in the presence of a protein kinase C pseudosubstrate peptide, but not a control peptide, inhi

186 ferent PDK1 inhibitors-BX-912 and a specific pseudosubstrate peptide-destabilized PKCiota.

187 tion similar to that seen for C with a bound pseudosubstrate peptide.

188 /-7.4% but was not affected by the scrambled pseudosubstrate peptide.

189 activators of PKC and not affected by a PKC pseudosubstrate peptide.

190 g unsuitable for phosphotransfer, as well as pseudosubstrate peptides of various lengths, we identify

191 Pharmacologic agents, isoform-selective pseudosubstrate peptides, and antisense oligonucleotides

192 ine phospholipase C (PC-PLC), PKC (including pseudosubstrate peptides, chelerythrine, and the alpha/b

193 KC-alpha activation by classical inhibitors, pseudosubstrate peptides, or the overexpression of domin

194 ease), a CaM-binding peptide, or CaM-KII/PKC pseudosubstrate peptides.

195 P and was therefore used to assess whether a pseudosubstrate perturbed the rate of holoenzyme dissoci

196 he region within PKR that interacts with the pseudosubstrate, pK3, is the same region that interacts

197 ere allosteric activators, by displacing the pseudosubstrate PKL region from the active site.

198 conformation of the ATP-binding site and the pseudosubstrate PKL-binding site.

199 tion by a Src kinase inhibitor and a PKCzeta-pseudosubstrate prevented eritoran-induced apoptosis.

200 The use of a PKCzeta pseudosubstrate prevented IL-1 from increasing ROS great

201 KA inhibitor (PKI) containing a specific PKA pseudosubstrate, R-R-N-A, was subcloned into a pTREX vec

202 Incubation with an aPKC pseudosubstrate recapitulates the phenotype of PKCiota k

203 f RSK1 competed with PKAc for binding to the pseudosubstrate region (amino acids 93-99) of PKARIalpha

204 Two recent studies identified the pseudosubstrate region and the C1 domain as direct membr

205 ased on the endogenous zeta protein kinase C pseudosubstrate region block agonist-induced adhesion to

206 Strikingly, we find that the RIalpha pseudosubstrate region is critically involved in forming

207 e PKAc, which requires Arg-95 and -96 in the pseudosubstrate region of PKARIalpha for their interacti

208 Thus, by competing for binding to the pseudosubstrate region of PKARIalpha, RSK1 regulates PKA

209 hat contains a sequence corresponding to the pseudosubstrate region of PKC-alpha (P1) partially rever

210 says, but PKC alpha constructs that lack the pseudosubstrate region or constructs of the whole cataly

211 We also find that PAK6 is regulated by the pseudosubstrate region, indicating a common type II PAK

212 as measured by phosphorylating the PKC-delta pseudosubstrate region-derived substrate was also reduce

213 -zeta (aPKCzeta), which lacks the N-terminal pseudosubstrate regulatory domain.

214 itutively autoinhibited, but mutation of the pseudosubstrate releases this inhibition and causes incr

215 ell polarity, and that addition of a PKCzeta pseudosubstrate restores osteoclastogenesis and bone res

216 I to the cell-free reactions containing CKII pseudosubstrates reversed the endocytosis block, suggest

217 l change, which displaces the amino-terminal pseudosubstrate segment from the active site.

218 terminal regulatory domain, which includes a pseudosubstrate segment that plugs the active site.

219 Our studies identify the core pseudosubstrate sequence (residues 297-300) but reveal t

220 ubstrate suggests that basic residues in the pseudosubstrate sequence are required for maintaining aP

221 We propose that in the absence of AMP this pseudosubstrate sequence binds to the active site groove

222 ially associated with the C subunit with the pseudosubstrate sequence docked in the active site cleft

223 ormational change in which an autoinhibitory pseudosubstrate sequence is released from the active sit

224 kinase C adopts a conformation in which its pseudosubstrate sequence is removed from the active site

225 kinase C adopts a conformation in which its pseudosubstrate sequence is removed from the active site

226 l five (or certain) arginine residues in the pseudosubstrate sequence of PKC-iota by site-directed mu

227 a myristoylated peptide corresponding to the pseudosubstrate sequence of protein kinase inhibitor (my

228 ntramolecularly (in cis) by methylation of a pseudosubstrate sequence on a flexible loop.

229 active site is blocked by binding either the pseudosubstrate sequence or a heterologous substrate.

230 ling that precursor protein kinase C has its pseudosubstrate sequence removed constitutively.

231 d in the central region of Acm1 constitute a pseudosubstrate sequence required for APC(Cdh1) inhibiti

232 hibitory peptide (ZIP) based on the PKC-zeta pseudosubstrate sequence reverses established LTP in vit

233 itive inhibition of substrate binding with a pseudosubstrate sequence within the holoenzyme.

234 PRKs are regulated by N-terminal domains, a pseudosubstrate sequence, Rho-binding domains, and a C2

235 diminished by autophosphorylation near this pseudosubstrate sequence.

236 M to residues associated with the inhibitory pseudosubstrate sequence.

237 hus, it is likely that Mei3-RKDIII defines a pseudosubstrate sequence.

238 hosphorylatable substrate-like sequence or a pseudosubstrate sequence.

239 N-Myristoylated peptides derived from the pseudosubstrate sequences of PKC isozymes were used to i

240 plays a high degree of conservation with the pseudosubstrate sequences of the protein kinase C (PKC)

241 and -eta were very similar to the endogenous pseudosubstrate sequences of these PKC isozymes, indicat

242 le of basic arginine residues common to aPKC pseudosubstrate sequences.

243 ugh PhK13-1 does not appear to function as a pseudosubstrate, several specificity determinants employ

244 The italicized amino acids form a putative pseudosubstrate site (Ser is replaced with Ala), which t

245 es that are juxtaposed to the autoinhibitory pseudosubstrate site in cGMP-dependent protein kinase ty

246 te that a conserved serine juxtaposed to the pseudosubstrate site in type I PKGs contributes importan

247 the pseudosubstrate site, but Arg-75 in the pseudosubstrate site is critical for autoinhibition.

248 h active kinases, kinase-dead PKC eta with a pseudosubstrate site mutation designed to give an active

249 res all four Arg residues (Arg-93-96) in the pseudosubstrate site of PKARIalpha.

250 from SLE T cells, one located adjacent to a pseudosubstrate site of the RI alpha subunit and the oth

251 wo copies of the cAMP-dependent kinase (PKA) pseudosubstrate site RRGAI.

252 lation site of Ibeta cGK is well outside the pseudosubstrate site, but Arg-75 in the pseudosubstrate

253 cGK enhances proteolysis within and near the pseudosubstrate site; treatment of dimeric cGK with thre

254 The domain containing PKA pseudosubstrate sites at the N terminus of PDE7A1 mediat

255 s as a conformational switch to position the pseudosubstrate so that it blocks the active site, a con

256 Pseudosubstrate-specific peptides with attached myristic

257 nitiated by the addition of Mg(2+) ions or a pseudosubstrate strand to the ribozyme, and the ensuing

258 ract the inhibitory effects of the exogenous pseudosubstrate suggests that basic residues in the pseu

259 e (FMP) on SERCA, producing a phosphorylated pseudosubstrate tethered to the nucleotide-binding site

260 Ebp2 thus acts like a pseudosubstrate that directly recruits Fbw7 to nucleoli.

261 in Roq1 binds the ubiquitin ligase Ubr1 as a pseudosubstrate, thereby modulating the degradation of s

262 essenger binding unleashes an autoinhibitory pseudosubstrate to allow substrate phosphorylation.

263 ddition of the exogenous arginine-containing pseudosubstrate tridecapeptide to inhibit this constitut

264 However, pseudosubstrates used to inhibit AGT activity have had l

265 paradoxical effects of the PKR mutations on pseudosubstrate vs. substrate interactions reflect diffe

266 sponsiveness to PIP3 was seen when exogenous pseudosubstrate was used to inhibit mouse liver PKC-lamb

267 ibits eIF-2alpha kinases by functioning as a pseudosubstrate, we observed that K3L directly interacte

268 is reversibly regulated by an autoinhibitory pseudosubstrate, which blocks the active site of the enz

269 A was also observed in the reaction with the pseudosubstrate, (Z)-3-fluorophosphoenolpyruvate, strong